Patents by Inventor Shai Erlich
Shai Erlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10570394Abstract: The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 1, 2016Date of Patent: February 25, 2020Assignee: Quark Pharmaceuticals, Inc.Inventors: Shai Erlich, James D. Thompson, Rabia Ozden, Elena Feinstein
-
Publication number: 20180305696Abstract: The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.Type: ApplicationFiled: December 5, 2017Publication date: October 25, 2018Inventors: Elizabeth C. Squiers, Shai Erlich, Daniel Rothenstein, Nir Sharon, Daniel J. Odenheimer, Elena Feinstein
-
Patent number: 10093923Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.Type: GrantFiled: October 27, 2015Date of Patent: October 9, 2018Assignee: NITTO DENKO CORPORATIONInventors: Xiaomei Jin, Lei Yu, Hirokazu Takahashi, Yasunobu Tanaka, Yoshiro Niitsu, Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett, Shai Erlich, Elizabeth C Squiers, Ning Chen
-
Patent number: 9868953Abstract: The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.Type: GrantFiled: July 14, 2017Date of Patent: January 16, 2018Assignee: Quark Pharmaceuticals, Inc.Inventors: Elizabeth C. Squiers, Shai Erlich, Daniel Rothenstein, Nir Sharon, Daniel J. Odenheimer, Elena Feinstein
-
Publication number: 20170335327Abstract: The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.Type: ApplicationFiled: July 14, 2017Publication date: November 23, 2017Inventors: Elizabeth C. Squiers, Shai Erlich, Daniel Rothenstein, Nir Sharon, Daniel J. Odenheimer, Elena Feinstein
-
Publication number: 20170081665Abstract: The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.Type: ApplicationFiled: May 27, 2015Publication date: March 23, 2017Applicant: Quark Pharmaceuticals, Inc.Inventors: Elizabeth C. Squiers, Shai Erlich, Daniel Rothenstein, Nir Sharon, Daniel J. Odenheimer, Elena Feinstein
-
Publication number: 20160304879Abstract: The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 1, 2016Publication date: October 20, 2016Inventors: Shai Erlich, James D. Thompson, Rabia Ozden, Elena Feinstein
-
Patent number: 9382542Abstract: The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 3, 2013Date of Patent: July 5, 2016Assignee: Quark Pharmaceuticals, Inc.Inventors: Shai Erlich, James D. Thompson, Rabia Ozden
-
Publication number: 20160108399Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.Type: ApplicationFiled: October 27, 2015Publication date: April 21, 2016Applicant: NITTO DENKO CORPORATIONInventors: Xiaomei JIN, Lei YU, Hirokazu TAKAHASHI, Yasunobu TANAKA, Yoshiro NIITSU, Elena FEINSTEIN, Sharon AVKIN-NACHUM, Hagar KALINSKI, Igor METT, Shai ERLICH, Elizabeth C. SQUIERS, Ning CHEN
-
Patent number: 9206424Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.Type: GrantFiled: March 18, 2014Date of Patent: December 8, 2015Assignee: NITTO DENKO CORPORATIONInventors: Xiaomei Jin, Lei Yu, Hirokazu Takahashi, Yasunobu Tanaka, Yoshiro Niitsu, Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett, Shai Erlich, Elizabeth C Squiers, Ning Chen
-
Publication number: 20140371439Abstract: The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 3, 2013Publication date: December 18, 2014Inventors: Shai Erlich, James D. Thompson, Rabia Ozden
-
Publication number: 20140235695Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.Type: ApplicationFiled: March 18, 2014Publication date: August 21, 2014Inventors: Xiaomei JIN, Lei YU, Hirokazu TAKAHASHI, Yasunobu TANAKA, Yoshiro NIITSU, Elena FEINSTEIN, Sharon AVKIN-NACHUM, Hagar KALINSKI, Igor METT, Shai ERLICH, Elizabeth C SQUIERS, Ning CHEN
-
Patent number: 8785408Abstract: The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.Type: GrantFiled: June 26, 2008Date of Patent: July 22, 2014Assignee: Quark Pharmaceuticals, Inc.Inventors: Elena Feinstein, Shai Erlich
-
Publication number: 20140140922Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: QUARK PHARMACEUTICALS, INC.Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
-
Patent number: 8710209Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.Type: GrantFiled: December 8, 2010Date of Patent: April 29, 2014Assignee: Nitto Denko CorporationInventors: Xiaomei Jin, Lei Yu, Hirokazu Takahashi, Yasunobu Tanaka, Yoshiro Niitsu, Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett, Shai Erlich, Elizabeth C. Squiers, Ning Chen
-
Patent number: 8637482Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.Type: GrantFiled: June 7, 2010Date of Patent: January 28, 2014Assignee: Quark Pharmaceuticals, Inc.Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
-
Publication number: 20120141378Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.Type: ApplicationFiled: June 7, 2010Publication date: June 7, 2012Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
-
Publication number: 20110178157Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.Type: ApplicationFiled: December 8, 2010Publication date: July 21, 2011Inventors: Xiaomei Jin, Lei Yu, Hirokazu Takahashi, Yasunobu Tanaka, Yoshiro Niitsu, Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett, Shai Erlich, Elizabeth C. Squiers